Literature DB >> 15775795

Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy.

George S Stergiou1, Thomas Makris, Maria Papavasiliou, Stamatis Efstathiou, Athanasios Manolis.   

Abstract

OBJECTIVE: To compare the additional antihypertensive effects of an angiotensin-converting enzyme inhibitor (ACEI), a dihydropyridine calcium antagonist and a diuretic in patients whose hypertension is not controlled by full-dose angiotensin receptor blocker (ARB) monotherapy. DESIGN AND METHODS: Individuals with an ambulatory blood pressure (ABP) that was not controlled by valsartan 160 mg once daily were allocated randomly to two groups: those in group A (n = 35) were assigned randomly to treatment with benazepril 20 mg once daily or chlorthalidone 12.5 mg once daily, whereas patients in group B (n = 29) were assigned randomly to benazepril 20 mg once daily or amlodipine 5 mg once daily. All individuals continued to receive background valsartan 160 mg once daily. After 5 weeks, patients crossed over to the alternative valsartan-based combination treatment of each group for a second 5-week period. Twenty-four-hour ABP monitoring was performed before the random allocation to groups and at the end of each randomized combination pharmacotherapy period.
RESULTS: Sixty-four individuals completed the study: 32 men and 32 women (mean +/- SD age 48.2 +/- 7.9 years, average 24-h ABP on valsartan monotherapy 143.4 +/- 12.6/87.7 +/- 7.8 mmHg). Significant additional antihypertensive effects on the average 24-h ABP were obtained with benazepril (8.6 +/- 8.8/6.3 +/- 6.7 mmHg), amlodipine (15.2 +/- 12.9/9.9 +/- 6.8 mmHg) and chlorthalidone (13.5 +/- 11.6/9.5 +/- 7.7 mmHg) (P < 0.001 for all additional antihypertensive effects). The additional effects of amlodipine and chlorthalidone added to valsartan were approximately 6/3.5 mmHg (P < 0.05) greater than that of benazepril.
CONCLUSIONS: In patients in whom hypertension was not controlled by full-dose ARB monotherapy, a diuretic, a calcium antagonist or an ACE inhibitor provided significant additional antihypertensive effect. The antihypertensive effects of the ARB-diuretic and the ARB-calcium antagonist combinations were superior to that of the ARB-ACE inhibitor combination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15775795     DOI: 10.1097/01.hjh.0000163159.22116.ab

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  17 in total

Review 1.  Dihydropyridine calcium channel antagonists in the management of hypertension.

Authors:  Benjamin J Epstein; Katherine Vogel; Biff F Palmer
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 2.  Antihypertensive Combination Treatment: State of the Art.

Authors:  M Burnier
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

3.  The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.

Authors:  Punnaka Pongpanich; Pasvich Pitakpaiboonkul; Kullaya Takkavatakarn; Kearkiat Praditpornsilpa; Somchai Eiam-Ong; Paweena Susantitaphong
Journal:  Int Urol Nephrol       Date:  2018-10-15       Impact factor: 2.370

Review 4.  Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.

Authors:  Carlos M Ferrario
Journal:  Life Sci       Date:  2009-12-01       Impact factor: 5.037

5.  Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact.

Authors:  Jean-Marie Krzesinski; Eric P Cohen
Journal:  Core Evid       Date:  2010-06-15

Review 6.  Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.

Authors:  Francesca Cagnoni; Christian Achiri Ngu Njwe; Augusto Zaninelli; Alessandra Rossi Ricci; Diletta Daffra; Antonio D'Ospina; Paola Preti; Maurizio Destro
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

Review 7.  Characterization and treatment of resistant hypertension.

Authors:  Roberto Pisoni; Mustafa I Ahmed; David A Calhoun
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

Review 8.  Direct renin inhibition: clinical pharmacology.

Authors:  Michel Azizi
Journal:  J Mol Med (Berl)       Date:  2008-03-27       Impact factor: 4.599

9.  Polytherapy with two or more antihypertensive drugs to lower blood pressure in elderly Ontarians. Room for improvement.

Authors:  Norman R C Campbell; Finlay A McAlister; Minh Duong-Hua; Karen Tu
Journal:  Can J Cardiol       Date:  2007-08       Impact factor: 5.223

Review 10.  Combination therapy with renin-angiotensin system blockers: will amlodipine replace hydrochlorothiazide?

Authors:  Thor Tejada; Alessia Fornoni; Oliver Lenz; Barry J Materson
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.